Editorial & Institutional Desk

Analyzing Dilution and Debt Risks at Nuo Therapeutics, Inc. (AURX)

By the PubCo Insight Editorial Desk, edited by Brad Listermann  ·  June 12, 2026
AURX
AURX Nuo Therapeutics, Inc.

Nuo Therapeutics, Inc. (AURX), a company operating in the surgical and medical instruments sector, has recently experienced a series of significant corporate developments. With a market capitalization of approximately 50.35 million dollars and 48.41 million shares outstanding, this OTC-traded micro-cap company requires careful scrutiny regarding its capital structure and financing activities. Recent regulatory filings indicate that the company is navigating new financial commitments that could impact shareholder value.

AURX price and volume
AURX price and volume, last 90 days. Source: Yahoo Finance.

According to an 8-K filed on June 3, 2026, Nuo Therapeutics entered into a material definitive agreement (Item 1.01) and incurred new direct financial obligations (Item 2.03). This filing also disclosed an unregistered sale of equity securities (Item 3.02). The combination of new debt obligations and unregistered equity sales represents a dual risk for retail investors. While the financing provides immediate capital, the unregistered equity issuance carries dilution risk for existing shareholders, and the new debt adds to the company's long-term financial liabilities.

The activity in early June 2026 was accompanied by other regulatory updates, including a Schedule 13D/A filed on June 3, 2026, which indicates changes in beneficial ownership. Additionally, Form 4 filings on June 2, 2026, and June 5, 2026, alongside a Form 4/A on June 2, 2026, show insider transaction activity. Earlier, on May 14, 2026, the company filed an 8-K containing its quarterly earnings release (Item 2.02). Investors should synthesize these disclosures to understand how the company's cash burn rate aligns with its newly acquired debt and equity financing.

SEC EDGAR filing alerts · $AURX

Get emailed the day $AURX files with the SEC.

Receive a source-linked alert when Nuo Therapeutics, Inc. posts a new 8-K, 10-Q, 10-K or S-1 on EDGAR, plus our Thursday flags and down-market holdouts briefing. Free, no buy or sell pitches.

We report that a filing exists and link to it. We do not tell you what to do. One click unsubscribes.

Primary sources (SEC EDGAR)

4 2026-06-05: https://www.sec.gov/Archives/edgar/data/1091596/000143774926019768/xslF345X06/rdgdoc.xmlSCHEDULE 13D/A 2026-06-03: https://www.sec.gov/Archives/edgar/data/1091596/000167475226000002/xslSCHEDULE_13D_X02/primary_doc.xml8-K 2026-06-03: https://www.sec.gov/Archives/edgar/data/1091596/000143774926019199/aurx20260602_8k.htm4 2026-06-02: https://www.sec.gov/Archives/edgar/data/1091596/000143774926019246/xslF345X06/rdgdoc.xml4/A 2026-06-02: https://www.sec.gov/Archives/edgar/data/1091596/000143774926019244/xslF345X06/rdgdoc.xml8-K 2026-05-14: https://www.sec.gov/Archives/edgar/data/1091596/000143774926017116/aurx20260514_8k.htm
Compiled by the PubCo Insight Editorial & Institutional Desk from primary SEC EDGAR disclosures and market data. Published for informational and research purposes only, not investment advice or a buy/sell recommendation.
Investor relations · AURX
Is this how AI describes Nuo Therapeutics, Inc.?
This page is the public, source-linked snapshot that investors, brokers, and AI assistants pull for AURX: EDGAR filings and recent news, no editor, no spin. When an AI engine or a financial terminal shows stale, misclassified, or missing data for your ticker, that is the first thing investors see. Pulse IR runs a free 24-hour audit of how ChatGPT, Perplexity, Google, and the major terminals currently represent AURX, and can correct it.
Get the free AI visibility audit
For company management and investor relations. Pulse IR is the investor-relations firm behind PubCo Insight.
See all AURX filings and data  ·  Uplist Radar  ·  Catalyst Radar  ·  Pulse IR Capital & Institutional Desk